Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.

نویسندگان

  • Frédéric Sacher
  • Vincent Probst
  • Philippe Maury
  • Dominique Babuty
  • Jacques Mansourati
  • Yuki Komatsu
  • Christelle Marquie
  • Antonio Rosa
  • Abou Diallo
  • Romain Cassagneau
  • Claire Loizeau
  • Raphael Martins
  • Michael E Field
  • Nicolas Derval
  • Shinsuke Miyazaki
  • Arnaud Denis
  • Akihiko Nogami
  • Philippe Ritter
  • Jean-Baptiste Gourraud
  • Sylvain Ploux
  • Anne Rollin
  • Adlane Zemmoura
  • Dominique Lamaison
  • Pierre Bordachar
  • Bertrand Pierre
  • Pierre Jaïs
  • Jean-Luc Pasquié
  • Mélèze Hocini
  • François Legal
  • Pascal Defaye
  • Serge Boveda
  • Yoshito Iesaka
  • Philippe Mabo
  • Michel Haïssaguerre
چکیده

BACKGROUND Implantable cardioverter-defibrillator indications in Brugada syndrome remain controversial, especially in asymptomatic patients. Previous outcome data are limited by relatively small numbers of patients or short follow-up durations. We report the outcome of patients with Brugada syndrome implanted with an implantable cardioverter-defibrillator in a large multicenter registry. METHODS AND RESULTS A total of 378 patients (310 male; age, 46±13 years) with a type 1 Brugada ECG pattern implanted with an implantable cardioverter-defibrillator (31 for aborted sudden cardiac arrest, 181 for syncope, and 166 asymptomatic) were included. Fifteen patients (4%) were lost to follow-up. During a mean follow-up of 77±42 months, 7 patients (2%) died (1 as a result of an inappropriate shock), and 46 patients (12%) had appropriate device therapy (5±5 shocks per patient). Appropriate device therapy rates at 10 years were 48% for patients whose implantable cardioverter-defibrillator indication was aborted sudden cardiac arrest, 19% for those whose indication was syncope, and 12% for the patients who were asymptomatic at implantation. At 10 years, rates of inappropriate shock and lead failure were 37% and 29%, respectively. Inappropriate shock occurred in 91 patients (24%; 4±4 shocks per patient) because of lead failure (n=38), supraventricular tachycardia (n=20), T-wave oversensing (n=14), or sinus tachycardia (n=12). Importantly, introduction of remote monitoring, programming a high single ventricular fibrillation zone (>210-220 bpm), and a long detection time were associated with a reduced risk of inappropriate shock. CONCLUSIONS Appropriate therapies are more prevalent in symptomatic Brugada syndrome patients but are not insignificant in asymptomatic patients (1%/y). Optimal implantable cardioverter-defibrillator programming and follow-up dramatically reduce inappropriate shock. However, lead failure remains a major problem in this population.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study.

BACKGROUND Brugada syndrome is an arrhythmogenic disease characterized by an increased risk of sudden cardiac death (SCD) by ventricular fibrillation. At present, an implantable cardioverter-defibrillator (ICD) is the recommended therapy in high-risk patients. This multicenter study reports the outcome of a large series of patients implanted with an ICD for Brugada syndrome. METHODS AND RESUL...

متن کامل

Implantable cardioverter-defibrillator in a patient with dextrocardia situs inversus

Background: Dextrocardia is a congenital anomaly, which may have coexistent coronary artery disease (CAD), arrhythmias and conventional indications for device therapy. However, the implantation of transvenous leads can be technically challenging and the approach needs to be tailored to the patient's individual anatomy. Case presentation: A 54-year-old male with dextrocardia situs inversus and i...

متن کامل

Diagnosis of Brugada Syndrome

Implantable cardioverter defibrillator (ICD) is considered to be the main therapy for prevention of sudden cardiac death in patients with Brugada syndrome (BrS). However, there have been several reports suggesting a higher prevalence of complications, such as inappropriate shocks, lead failure, and device infection compared with the incidence of lethal ventricular arrhythmia. BrS is mainly diag...

متن کامل

Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome

Frédéric Sacher, MD; Vincent Probst, MD, PhD; Yoshito Iesaka, MD; Peggy Jacon, MD; Julien Laborderie, MD; Frédérique Mizon-Gérard, MD; Philippe Mabo, MD; Sylvain Reuter, MD; Dominique Lamaison, MD; Yoshihide Takahashi, MD; Mark D. O’Neill, MB, BCh, DPhil; Stéphane Garrigue, MD, PhD; Bertrand Pierre, MD; Pierre Jaïs, MD; Jean-Luc Pasquié, MD, PhD; Mélèze Hocini, MD; Michèle Salvador-Mazenq, MD; ...

متن کامل

Importance of exercise testing shortly after subcutaneous implantable cardioverter-defibrillator implantation in patients with Brugada syndrome – The first case of associated inappropriate shock in Japan

We report the case of a 51-year-old patient with Brugada syndrome (BrS) who experienced inappropriate shock due to T-wave oversensing (TWOS) during exercise when the optimal sensing vector was selected based on the automatic analysis by a subcutaneous implantable cardioverter-defibrillator (S-ICD). After selecting another vector during exercise testing, TWOS did not re-occur. Selection of appro...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Circulation

دوره 128 16  شماره 

صفحات  -

تاریخ انتشار 2013